Pharma News, 2018

Teva Pharmaceutical Industries has decided not to pursue development of laquinimod, and has returned rights to the drug back to Swedish group Active Biotech.

In yet another indication of what the burden of Brexit will be for drug manufacturers, Pfizer has said that it has tallied its costs to revise its manufacturing and supply chain at about $100 million.

Every smell, from a rose to a smoky fire to a pungent fish, is composed of a mixture of odorant molecules that bind to protein receptors inside your nose.

A federal judge has dismissed a lawsuit seeking to block a California law requiring pharmaceutical companies to give advance notice before big price increases.

Theranos, the blood-testing company accused of perpetrating Silicon Valley's biggest fraud, will soon cease to exist.

BEIJING, Sept.

The inherited gene that leads to Huntington’s disease has been found to affect brain development from an early age, even though most patients don’t develop symptoms of the disease until they are b...

Four in five people have a heart age older than their real age, leaving them at risk of early death from cardiovascular disease, Public Health England data show.

Pfizer is shutting down two clinical studies assessing the anti-myostatin monoclonal antibody domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD).

Bad Vilbel, September 3, 2018 – Peter Goldschmidt (53) succeeded Claudio Albrecht as the Chief Executive Officer of STADA Arzneimittel AG (‘STADA’ or ‘the Group’) with effec...

The life-threatening, autoimmune-based blood clotting disorder leads to severe thrombocytopenia, microangiopathic hemolytic anemia, ischemia and organ damage, particularly of the brain and heart.

Not that it’s a competition, but after the U.